...
首页> 外文期刊>AIDS Research and Human Retroviruses >Graft-versus-tumor effect after allogeneic stem cell transplantation in HIV-positive patients with high-risk hematologic malignancies
【24h】

Graft-versus-tumor effect after allogeneic stem cell transplantation in HIV-positive patients with high-risk hematologic malignancies

机译:同种异体干细胞移植对HIV阳性高危血液恶性肿瘤患者的移植物抗肿瘤作用

获取原文
获取原文并翻译 | 示例
           

摘要

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a well-established therapeutic option for hematological malignancies. Combination antiretroviral therapy (cART) has enabled the treatment of medical conditions in patients infected with the human immunodeficiency virus (HIV) in the same way as in the general population. Moreover, improvements in supportive care have allowed HIV-infected patients with life-threatening hematological disorders to be treated with Allo-HSCT. We report on four HIV-infected patients with hematological malignancies receiving an Allo-HSCT in our institution, and on the use of donor lymphocyte infusions to successfully treat post-Allo-HSCT relapse. Of note, one of them is the first HIV+ patient to receive a "dual transplant" (unrelated umbilical cord blood stem cells combined with mobilized T cell-depleted CD34+ stem cells from a mismatched third party donor). CART drugs interactions were satisfactorily managed. This approach provided long-term control of the hematological disease. Nevertheless, despite adequate immune reconstitution, infections were the main cause of morbidity and mortality after Allo-HSCT.
机译:同种异体造血干细胞移植(Allo-HSCT)是血液系统恶性肿瘤公认的治疗选择。联合抗逆转录病毒疗法(cART)能够以与普通人群相同的方式治疗感染了人类免疫缺陷病毒(HIV)的患者的疾病。而且,支持治疗的改善使艾滋-HSCT治疗了感染艾滋病毒并危及生命的血液病患者。我们报告了在我们机构中接受Allo-HSCT的四名HIV感染的血液系统恶性肿瘤患者,以及使用供体淋巴细胞输注成功治疗Allo-HSCT后复发的报道。值得注意的是,其中一位是第一位接受“双重移植”(不相关的脐带血干细胞与来自失配的第三方供体的动员的T细胞耗尽的CD34 +干细胞的组合)的HIV +患者。 CART药物相互作用得到了令人满意的管理。这种方法可长期控制血液病。尽管如此,尽管进行了充分的免疫重建,但感染仍是Allo-HSCT后发病和死亡的主要原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号